ArriVent BioPharma, Inc.
AVBP
$29.79
-$0.49-1.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -164.21M | -145.24M | -166.31M | -150.98M | -136.79M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.46M | 12.15M | 9.49M | 9.83M | 7.21M |
| Change in Net Operating Assets | 818.00K | -1.38M | -3.77M | -4.94M | 2.95M |
| Cash from Operations | -147.93M | -134.47M | -160.59M | -146.08M | -126.63M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.31M | -104.47M | -71.23M | -192.49M | -141.73M |
| Cash from Investing | -72.31M | -104.47M | -71.23M | -192.49M | -141.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 261.87M | 251.20M | 203.13M | 168.45M | 82.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 283.00K | -20.00K | -70.00K | -53.00K | -353.00K |
| Cash from Financing | 262.15M | 251.18M | 203.06M | 168.39M | 82.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 41.92M | 12.24M | -28.75M | -170.18M | -185.90M |